Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

STORM: Temsirolimus, Rituximab and DHAP for Relapsed and Refractory Diffuse Large B-cell Lymphoma (STORM)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Johannes Gutenberg University Mainz
Technische Universität München
Ludwig-Maximilians - University of Munich
University Hospital Ulm
University Hospital Erlangen
Charite University, Berlin, Germany
University Hospital Freiburg
Johann Wolfgang Goethe University Hospital
Information provided by (Responsible Party):
Mathias Witzens-Harig, University Hospital Heidelberg
ClinicalTrials.gov Identifier:
NCT01653067
First received: July 17, 2012
Last updated: October 26, 2016
Last verified: October 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: July 2018
  Estimated Primary Completion Date: June 2018 (Final data collection date for primary outcome measure)
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):